Neurodyn Cognition (NCI), a Canadian company developing an intranasal therapy for Alzheimer’s disease, has named Anthony Giovinazzo as a director and Executive Chairman. Giovinazzo was most recently President and CEO of Cynapsus Therapeutics, which was sold to Sunovion in 2016.
NCI’s Memogain is described as an intranasal formulation of a prodrug of galantamine, which is an approved treatment for Alzheimer’s. The company said that it is raising funds for Phase 2 development of the product.
Giovinazzo said, “I am looking forward to joining the NCI team and assisting the company in completing the successful development and commercialization of Memogain, which could represent a near term commercialization opportunity for the underserved Alzheimer’s market.”
NCI CEO Kenneth Cawkell commented, “We are pleased to welcome Anthony Giovinazzo to the NCI Board as our Executive Chairman. Anthony has a tremendous background in drug development and, equally important, in securing the required financing. His experience will be a significant benefit to the company as we move forward with the next phase of Memogain’s clinical development program.”
Read the NCI press release.
